These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 24982363)

  • 1. ABCB1 polymorphism as a predictive biomarker for amrubicin-induced neutropenia.
    Takakuwa O; Oguri T; Uemura T; Kunii E; Nakao M; Hijikata H; Kawaguchi Y; Ohkubo H; Takemura M; Maeno K; Niimi A
    Anticancer Res; 2014 Jul; 34(7):3517-22. PubMed ID: 24982363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.
    Takakuwa O; Oguri T; Ozasa H; Uemura T; Kunii E; Kasai D; Miyazaki M; Maeno K; Sato S
    J Thorac Oncol; 2011 Nov; 6(11):1826-32. PubMed ID: 21964527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
    von Pawel J; Jotte R; Spigel DR; O'Brien ME; Socinski MA; Mezger J; Steins M; Bosquée L; Bubis J; Nackaerts K; Trigo JM; Clingan P; Schütte W; Lorigan P; Reck M; Domine M; Shepherd FA; Li S; Renschler MF
    J Clin Oncol; 2014 Dec; 32(35):4012-9. PubMed ID: 25385727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer.
    Watanabe H; Ikesue H; Oshiro M; Nagata K; Mishima K; Takada A; Suetsugu K; Sueyasu M; Egashira N; Harada T; Takayama K; Nakanishi Y; Oishi R
    Chemotherapy; 2012; 58(6):419-25. PubMed ID: 23295219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender difference in hematological toxicity among lung cancer patients receiving amrubicin monotherapy.
    Makihara RA; Makino Y; Yamamoto N; Yokote N; Nokihara H; Sekine I; Ohe Y; Tamura T; Yamamoto H
    Jpn J Clin Oncol; 2012 Dec; 42(12):1187-91. PubMed ID: 23081985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.
    Makino Y; Makihara-Ando R; Ogawa T; Sato H; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Ohe Y; Yamamoto N
    Cancer Sci; 2019 Nov; 110(11):3573-3583. PubMed ID: 31505087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
    Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M
    Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of amrubicin hydrochloride and cisplatin in patients previously treated for advanced non-small cell lung cancer.
    Ikeda J; Maruyama R; Okamoto T; Shoji F; Wataya H; Ichinose Y
    Jpn J Clin Oncol; 2006 Jan; 36(1):12-6. PubMed ID: 16418184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.
    Okamoto I; Hamada A; Matsunaga Y; Sasaki J; Fujii S; Uramoto H; Yamagata H; Mori I; Kishi H; Semba H; Saito H
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):282-8. PubMed ID: 16028099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial.
    Kitagawa C; Saka H; Kajikawa S; Mori K; Oki M; Suzuki R
    Cancer Chemother Pharmacol; 2012 May; 69(5):1379-85. PubMed ID: 22237957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
    Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
    J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
    van der Holt B; Van den Heuvel-Eibrink MM; Van Schaik RH; van der Heiden IP; Wiemer EA; Vossebeld PJ; Löwenberg B; Sonneveld P
    Clin Pharmacol Ther; 2006 Nov; 80(5):427-39. PubMed ID: 17112800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.
    Asao T; Nokihara H; Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Yamamoto N; Sekine I; Kunitoh H; Fujiwara Y; Ohe Y
    Jpn J Clin Oncol; 2015 Oct; 45(10):941-6. PubMed ID: 26232449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese.
    Hamajima N; Matsuo K; Iwata H; Shinoda M; Yamamura Y; Kato T; Hatooka S; Mitsudomi T; Suyama M; Kagami Y; Ogura M; Ando M; Sugimura Y; Tajima K
    Int J Clin Oncol; 2002 Apr; 7(2):103-8. PubMed ID: 12018106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.
    Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K
    Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer.
    Wong M; Evans S; Rivory LP; Hoskins JM; Mann GJ; Farlow D; Clarke CL; Balleine RL; Gurney H
    Clin Pharmacol Ther; 2005 Jan; 77(1):33-42. PubMed ID: 15637529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
    Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose escalation and feasibility study of amrubicin combined with cisplatin in previously untreated patients with advanced non-small cell lung cancer.
    Yoshimura N; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Ichimaru Y; Hirata K; Kudoh S
    Am J Clin Oncol; 2013 Apr; 36(2):105-9. PubMed ID: 22270109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
    Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of amrubicin as a third or later line of chemotherapy for advanced non-small cell lung cancer.
    Igawa S; Sasaki J; Ishihara M; Otani S; Maki S; Hiyoshi Y; Kasajima M; Katono K; Takakura A; Masuda N
    Chemotherapy; 2013; 59(2):99-105. PubMed ID: 24021914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.